TCGA-CR-7393-01A-11R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.460
- KRAS_SIGNALING_UP+0.440
- ALLOGRAFT_REJECTION+0.430
- HEDGEHOG_SIGNALING+0.410
- INFLAMMATORY_RESPONSE+0.380
- APICAL_SURFACE+0.370
- IL6_JAK_STAT3_SIGNALING+0.370
- TNFA_SIGNALING_VIA_NFKB+0.340
- IL2_STAT5_SIGNALING+0.330
- TGF_BETA_SIGNALING+0.330
Top 10 suppressed
- MYC_TARGETS_V2-0.660
- E2F_TARGETS-0.650
- MYC_TARGETS_V1-0.640
- OXIDATIVE_PHOSPHORYLATION-0.550
- G2M_CHECKPOINT-0.530
- DNA_REPAIR-0.490
- MTORC1_SIGNALING-0.450
- UNFOLDED_PROTEIN_RESPONSE-0.410
- GLYCOLYSIS-0.340
- INTERFERON_ALPHA_RESPONSE-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-75-7030-01A-11R-1949-07 | — | cohortA1 | 0.955 |
| 2 | ULC1729T_S65 | — | cohortSQ1 | 0.936 |
| 3 | TCGA-A2-A0ES-01A-11R-A115-07 | — | A | 0.925 |
| 4 | TCGA-38-7271-01A-11R-2039-07 | — | cohortMD2 | 0.925 |
| 5 | TCGA-A2-A0EW-01A-21R-A115-07 | — | A | 0.920 |
| 6 | TCGA-4Z-AA7N-01A-11R-A39I-07 | — | — | 0.918 |
| 7 | SRR12475153 | — | — | 0.918 |
| 8 | TCGA-CU-A0YO-01A-11R-A10U-07 | — | — | 0.917 |
| 9 | SRR35579845 | — | A | 0.916 |
| 10 | 20020074.LumA | — | A | 0.915 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.460 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.440 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.430 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.410 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.370 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.330 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.330 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.320 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.230 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |